---
title: "NCODA Immunotherapy Hub"
canonical: "/ncoda-immunotherapy-hub"
published: 2026-09-24
---

# NCODA Immunotherapy Hub

## Section · 1 Hero

NCODA IMMUNOTHERAPY HUB

Practical Resources for CAR-T Cell Therapyand Bispecific T-Cell Engagers

Clinical education, therapy-specific guidance, and implementation tools for multidisciplinary oncology care teams.

Choose a hub to explore available resources.

## Section · 2 Hub cards

NOW LIVE

COMING SOON

Bispecific T-Cell Engager Hub

CAR-T Cell Therapy Hub

HUB 01

HUB 02

Bispecific T-Cell Engager Hub

CAR-T Cell Therapy Hub

Practical resources to support implementation of bispecific T-cell engagers across care settings, including step-up dosing, toxicity management, patient education, and workflow support.

Practical resources supporting CAR-T cell therapy across key stages of care, from referral and apheresis through infusion and post-treatment monitoring.

- Foundations clinical education
- “Up Close” agent-specific resources for FDA-approved CAR-T therapies
- Example SOPs and clinic implementation toolkits

- Foundational clinical education and microlearning
- "Up Close" agent-specific resources for FDA-approved bispecific T-cell engager therapies
- Example SOPs and real-world practice documents

**Explore the Bispecific T-Cell Engager Hub →**

**Coming Soon the CAR-T Hub →**

## Section · 3 At a Glance

AT A GLANCE

Two approaches. One goal.

Both approaches use T-cells to target cancer, but they differ in how treatment is prepared, delivered and monitored.

BISPECIFIC T-CELL ENGAGERS

CAR-T CELL THERAPY

How it works

A bispecific molecule binds a T-cell target, typically CD3, and a tumor-associated target, bringing the cells into close proximity and activating T-cell–mediated killing.

A patient’s T cells are collected and genetically modified to express a chimeric antigen receptor that recognizes a tumor-associated antigen.

Product

Ready-to-use drug product; does not require individualized cell manufacturing.

Patient-specific cell product; current autologous CAR-T therapies require leukapheresis and individualized manufacturing.

Administration

Repeated dosing; most current products begin with a step-up dosing schedule.

Typically a single CAR-T infusion following lymphodepleting chemotherapy.

Selected safety considerations

CRS, neurologic toxicity including ICANS, infections, and cytopenias; timing and monitoring vary by product.

CRS, neurologic toxicity including ICANS, infections, cytopenias, and other product-specific risks.

Care setting

Inpatient and outpatient settings; monitoring requirements vary by product, indication, patient, and institutional protocol.

Specialized treatment programs with coordinated referral and shared-care pathways.

General educational overview. Requirements, monitoring, and risks vary by product and indication. Refer to current prescribing information and institutional protocols.

## Section · 4 Inside the Hubs

WHAT YOU'LL FIND

Built for multidisciplinary oncology teams

Each hub brings together clinical education, therapy-specific guidance, and practical tools to support real-world implementation.

Support Real-World Implementation

Example SOPs, workflow tools, and practice resources

Access Therapy-Specific Guidance

Practical, agent-specific resources for CAR-T cell therapy and bispecific T-cell engagers

Build Foundational Knowledge

Clinical overviews and educational resources.

## Section · 5 Closing CTA

Advancing immunotherapy, together.

**Bispecific T-Cell Engager Hub**

→

**CAR-T Cell Therapy Hub**

Start with the hub that fits your practice today — and check back as NCODA continues to expand its immunotherapy resources.

→